| 1.94 -0.02 (-1.02%) | 10-08 15:15 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 2.51 | 1-year : | 2.93 |
| Resists | First : | 2.15 | Second : | 2.51 |
| Pivot price | 2  |
|||
| Supports | First : | 1.87 | Second : | 1.71 |
| MAs | MA(5) : | 2.03 |
MA(20) : | 1.96 |
| MA(100) : | 2.68 |
MA(250) : | 2.29 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 55 |
D(3) : | 69.9 |
| RSI | RSI(14): 46.1 |
|||
| 52-week | High : | 3.93 | Low : | 0.5 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ HRTX ] has closed above bottom band by 27.0%. Bollinger Bands are 70.3% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 29 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 2.13 - 2.14 | 2.14 - 2.15 |
| Low: | 1.92 - 1.93 | 1.93 - 1.94 |
| Close: | 1.94 - 1.96 | 1.96 - 1.97 |
Heron Therapeutics, Inc., a biotechnology company, engages in developing treatments to address unmet patient needs. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; HTX-019, an investigational agent for the prevention of postoperative nausea and vomiting; and HTX-034 for postoperative pain management, as well as is in Phase Ib/II clinical study in patients undergoing bunionectomy. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California.
Thu, 03 Oct 2024
When Can We Expect A Profit From Heron Therapeutics, Inc. (NASDAQ:HRTX)? - Simply Wall St
Wed, 02 Oct 2024
Heron Therapeutics, Inc.'s (NASDAQ:HRTX) Path To Profitability - Yahoo Finance
Wed, 25 Sep 2024
Heron stock gains on FDA nod for Zynrelef method (NASDAQ:HRTX) - Seeking Alpha
Wed, 25 Sep 2024
Heron Therapeutics Announces FDA Approval of the Prior Approval Supplement Application for ZYNRELEF® Vial Access Needle ("VAN") - StockTitan
Wed, 11 Sep 2024
Heron Therapeutics: Zynrelef Developments Are Unlikely To Provide Relief To Investors - Seeking Alpha
Thu, 08 Aug 2024
Investors Don't See Light At End Of Heron Therapeutics, Inc.'s (NASDAQ:HRTX) Tunnel And Push Stock Down 32% - Simply Wall St
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 152 (M) |
| Shares Float | 116 (M) |
| Held by Insiders | 0.6 (%) |
| Held by Institutions | 86.8 (%) |
| Shares Short | 35,440 (K) |
| Shares Short P.Month | 35,960 (K) |
| EPS | -0.25 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -0.25 |
| Profit Margin | -35.3 % |
| Operating Margin | -17.9 % |
| Return on Assets (ttm) | -8.6 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 13.3 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0.89 |
| EBITDA (p.s.) | -0.18 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -21 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | -7.81 |
| PEG Ratio | -0.5 |
| Price to Book value | -7.81 |
| Price to Sales | 2.16 |
| Price to Cash Flow | -14.2 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|